The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Infectious Diseases Clinical Trials Network (IDCTN)" aimed at advancing public health through the rapid implementation of clinical trials for infectious diseases. This initiative seeks to establish a network comprising Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC) to evaluate therapeutics, vaccines, diagnostics, and devices, addressing urgent public health needs that standard grant timelines cannot meet. With an estimated total program funding of $29 million, this opportunity is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, and community-based organizations. Interested parties can reach out to Dr. Marina S. Lee at 240-627-3304 or via email at dmidclinicaltrials@niaid.nih.gov for further information, with key deadlines including an estimated synopsis close date of June 11, 2026, and an anticipated award date of March 1, 2027.

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting a cooperative network to rapidly implement clinical trials that meet NIH and NIAID priorities. The network, comprised of the Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC), supports the evaluation of therapeutics, vaccines, biologics, diagnostics, and devices targeting infectious diseases, including emerging and chronic infections. The initiative gives the NIH the capabilities to conduct clinical trials and studies for public health priorities, where the timelines of a standard, unsolicited grant would not adequately address the needs of the United States population. The CTEUs provide the clinical infrastructure for implementing the clinical trials and studies. The NCC, comprised of leaders from the CTEUs in collaboration with NIAID, provides the administrative and organizational framework of the network, engages with experts in the field to solicit and generate innovative concepts for advancing public health while mentoring the next generation of clinical trialists. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

Buyer

Eligible Applicants

Funding Category

Funding Instrument

Opportunity Category

Cost Sharing or Matching Requirement

Original Source